Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201669 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00201669 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT00201669, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will determine the efficacy of clofarabine as measured by response rate in patients with aggressive non-Hodgkin's lymphoma
Interventions
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201669
The ClinicalTrials.gov registry entry for NCT00201669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clofarabine is the first listed.
NCT00201669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201669 about?
NCT00201669 is a clinical study titled "A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma". This study will determine the efficacy of clofarabine as measured by response rate in patients with aggressive non-Hodgkin's lymphoma
What is the current status of trial NCT00201669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2004-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00201669?
The interventions under investigation include: Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00201669?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.